Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Vykat XR Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.PHAR.701

    Clinical Policy: Diazoxide Choline (Vykat XR)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.701 alerts

    Get alerted when Policy CP.PHAR.701 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage of Vykat XR for hyperphagia in adults and pediatric members age 4 years and older with Prader-Willi syndrome. It applies to Ambetter Nevada commercial, HIM/ICHRA, and Medicaid lines of business, subject to applicable benefit documents and state Medicaid requirements.

    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Diazoxide Choline (Vykat XR)
    Policy CodePolicy CP.PHAR.701
    Change TypeMaterial revision
    Effective DateMar 26, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation confirming all applicable approval criteria, including genetic confirmation of PWS, specialist prescribing or consultation, age, weight, baseline HQ-CT score, and requested dose.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual revision added the health insurance marketplace/ICHRA line of business.

    The PWS diagnosis criterion was revised to require genetic testing indicating a mutation on chromosome 15.

    The policy previously removed the upper weight limit of 135 kg and several continued-therapy response parameters, including CGI-I, GI-C, body-composition components, and behavioral improvements.

    The continued-therapy approval duration was revised from 6 months to 12 months.

    ≥4 yearsMinimum age
    ≥20 kgMinimum weight

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥13Baseline HQ-CT
    5.8 mg/kg/day or 525 mg/dayMaximum dose
    6 mo / 12 moApproval duration
    25/75/150 mgTablet strengths

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ONE of the following pathways is met. Approval duration: 6 months.

    ONE of the following pathways

    • Prader-Willi Syndrome

      • Diagnosis of Prader-Willi syndrome confirmed by genetic testing indicating a mutation on chromosome 15.
      • Prescribed by or in consultation with a pediatric endocrinologist or geneticist.
      • Member is age 4 years or older.>= 4 years
      • Member weighs at least 20 kg.>= 20 kg
      • Baseline Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score is documented and is at least 13 (see Appendix D).>= 13
      • Both dosing limits must be met

        • Dose does not exceed 5.8 mg/kg per day.<= 5.8 mg/kg/day
        • Dose does not exceed 525 mg per day.<= 525 mg/day
    • Other diagnoses or indications — ONE of the following

      • Recent label change pathway

        • If the drug has undergone a label change within the last 6 months (for example, a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy, refer to the applicable no-coverage-criteria policy for the relevant line of business when the drug is on the formulary or PDL: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
        • If the drug has undergone a label change within the last 6 months (for example, a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy, refer to the applicable non-formulary policy for the relevant line of business when the drug is not on the formulary or PDL: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
      • Off-label use pathway

        • The requested use (for example, diagnosis, age, or dosing regimen) is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.

    Continuation Therapy

    Covered for continued therapy when ONE of the following pathways is met. Approval duration: 12 months.

    ONE of the following pathways

    • Prader-Willi Syndrome

      • ONE of the following access conditions

        • Currently receiving the medication through a Centene benefit.
        • Previously met the initial approval criteria.
        • Currently receiving the medication and is enrolled in a state and product with continuity-of-care regulations; refer to state-specific addenda CC.PHARM.03A and CC.PHARM.03B.
      • Member is responding positively to therapy, as evidenced by a reduction in the overall HQ-CT total score from baseline.

    Non-FDA-approved indications that are not addressed in this policy are not authorized for coverage unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy or evidence of coverage documents: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.

    Coverage is contraindicated for members with known hypersensitivity to diazoxide, any other component of Vykat XR, or thiazides.

    Clinical Thresholds and Coding Parameters

    Minimum Age
    Minimum ageAt least 4 years
    Applies toInitial approval for Prader-Willi syndrome
    Age criterionThe member must be age 4 years or older when Vykat XR is requested
    Minimum Weight
    Minimum weightAt least 20 kg
    Applies toInitial approval for Prader-Willi syndrome
    Weight criterionThe member must weigh 20 kg or more when Vykat XR is requested

    Authorization and Documentation Requirements

    Documentation Required

    Documentation Required for Authorization

    Provider-submitted documentation is required for authorization. Submit documentation supporting that the member meets all applicable approval criteria for Vykat XR.

    Documentation Required

    Initial Clinical Documentation

    For an initial request, submit office chart notes, laboratory results, or other clinical information supporting each applicable Prader-Willi syndrome approval criterion.

    • Genetic testing confirming Prader-Willi syndrome with a mutation on chromosome 15.
    • Prescriber documentation showing prescription by, or consultation with, a pediatric endocrinologist or geneticist.
    • Member age of ≥ 4 years and weight of ≥ 20 kg.
    • Baseline HQ-CT score of ≥ 13, when applicable.
    • Requested dose does not exceed 5.8 mg/kg/day and 525 mg/day.

    Clinical Background

    Diazoxide choline extended-release tablets (Vykat XR) are an ATP-dependent potassium channel agonist. Vykat XR is FDA-approved to treat hyperphagia in adults and pediatric patients 4 years and older with Prader-Willi syndrome (PWS), a condition associated with excessive, persistent hunger and hyperphagia-related behaviors.

    Definitions

    ATP
    AbbreviationATP
    Expanded termAdenosine triphosphate
    Drug classATP-dependent potassium channel agonist
    HQ-CT
    AbbreviationHQ-CT
    Full nameHyperphagia Questionnaire for Clinical Trials
    Assessment formatA 9-question, caregiver-completed questionnaire assessing PWS hyperphagia-related behaviors over a 2-week recall period; total scores range from 0 to 36

    Vykat XR Initial Therapy

    Vykat XR Initial Therapy

    Initial Vykat XR therapy for Prader-Willi syndrome is covered when all criteria are met.

    Vykat XR initial PWS criteria

    • Prader-Willi syndrome is confirmed by genetic testing indicating a mutation on chromosome 15.
    • Vykat XR is prescribed by or in consultation with a pediatric endocrinologist or geneticist.
    • The member is at least 4 years old.≥ 4 years
    • The member weighs at least 20 kg.≥ 20 kg

    Vykat XR Continuation Therapy

    Vykat XR Continuation Therapy

    Continued Vykat XR therapy for Prader-Willi syndrome is covered when all criteria are met.

    Vykat XR continuation PWS criteria

    • Prior therapy or continuity of care

      • The member is currently receiving medication through a Centene benefit or previously met the initial approval criteria.
      • The member is currently receiving medication and is enrolled in a state and product with continuity-of-care regulations.

        Refer to state-specific addenda CC.PHARM.03A and CC.PHARM.03B.

    • The member is responding positively to therapy, evidenced by a reduction in the overall HQ-CT total score from baseline.

    Vykat XR Quantity Limits

    Vykat XR Quantity Limit
    MedicationVykat XR
    Maximum dose5.8 mg/kg/day
    Administration limitThe weight-based dose must not exceed 5.8 mg per kilogram per day
    Vykat XR Quantity Limit
    MedicationVykat XR
    Maximum dose525 mg/day
    Administration limitThe total daily dose must not exceed 525 mg per day
    Policy Summary
    PayerAmbetter Nevada
    PolicyClinical Policy: Diazoxide Choline (Vykat XR)
    Policy CodePolicy CP.PHAR.701
    Change TypeMaterial revision
    Effective DateMar 26, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit clinical documentation confirming all applicable approval criteria, including genetic confirmation of PWS, specialist prescribing or consultation, age, weight, baseline HQ-CT score, and requested dose.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding ParametersAuthorization and Documentation RequirementsClinical BackgroundDefinitionsVykat XR Initial TherapyVykat XR Continuation TherapyVykat XR Quantity Limits
    The recent label change pathway above does not apply.
  1. Refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  2. If requesting a dose increase, both dosing limits must be met

    • The new dose does not exceed 5.8 mg/kg per day.<= 5.8 mg/kg/day
    • The new dose does not exceed 525 mg per day.<= 525 mg/day
  3. Other diagnoses or indications — ONE of the following

    • Recent label change pathway

      • If the drug has undergone a label change within the last 6 months (for example, a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy, refer to the applicable no-coverage-criteria policy for the relevant line of business when the drug is on the formulary or PDL: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
      • If the drug has undergone a label change within the last 6 months (for example, a newly approved indication, age expansion, or new dosing regimen) that is not yet reflected in this policy, refer to the applicable non-formulary policy for the relevant line of business when the drug is not on the formulary or PDL: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
    • Off-label use pathway

      • The requested use (for example, diagnosis, age, or dosing regimen) is not specifically listed under Section III, Diagnoses/Indications for which coverage is NOT authorized.
      • The recent label change pathway above does not apply.
      • Refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.
  4. Baseline HQ-CT Score
    Required baseline scoreHQ-CT score of at least 13
    AssessmentThe baseline Hyperphagia Questionnaire for Clinical Trials score must be documented
    Scoring contextThe HQ-CT total possible score ranges from 0 to 36
    Maximum Daily Dose
    Weight-based maximum5.8 mg/kg/day
    Absolute maximum525 mg/day
    Dose requirementThe dose must not exceed both limits
    Documentation Required

    Continuation Documentation

    Continuation requests must document qualifying prior therapy or continuity-of-care status, positive response to treatment, and compliance with dose limits for any dose increase.

    • Member is currently receiving Vykat XR through the Centene benefit or previously met initial approval criteria; or the member is receiving the medication under a state and product subject to continuity-of-care regulations, consistent with the applicable state-specific addenda.
    • Positive response demonstrated by a reduction in the overall HQ-CT total score from baseline.
    • For a dose increase, the new dose does not exceed 5.8 mg/kg/day or 525 mg/day.
    Denial Risk

    Initial Criteria Not Met

    An initial Prader-Willi syndrome request is not authorized when the required diagnosis, specialist involvement, clinical thresholds, or dosing requirements are not documented or are not met.

    • PWS is not confirmed by genetic testing indicating a mutation on chromosome 15.
    • The prescription is not from, or made in consultation with, a pediatric endocrinologist or geneticist.
    • Member is younger than 4 years or weighs less than 20 kg.
    • Baseline HQ-CT score is less than 13 or is not documented.
    • Requested dose exceeds either 5.8 mg/kg/day or 525 mg/day.
    Denial Risk

    Continuation Criteria Not Met

    A continuation request is not authorized when qualifying prior therapy or continuity-of-care requirements, documented positive response, or applicable dose limits are not met.

    • Member does not meet the prior-therapy requirement and is not eligible under applicable continuity-of-care regulations.
    • There is no documented reduction in the overall HQ-CT total score from baseline.
    • For a dose increase, the new dose exceeds 5.8 mg/kg/day or 525 mg/day.
    Denial Risk

    Unauthorized Indication or Contraindication

    Coverage is not authorized for non-FDA-approved indications not addressed by this policy unless sufficient efficacy and safety documentation supports an applicable off-label coverage pathway. Vykat XR is also contraindicated for members with known hypersensitivity to diazoxide, another Vykat XR component, or thiazides.

    • Non-FDA-approved indications may be considered only under the applicable off-label use policy: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid, or under applicable evidence of coverage documents.
    • Do not authorize use in members with known hypersensitivity to diazoxide, other Vykat XR components, or thiazides.
    • No boxed warnings are reported in the policy.
    PWS
    AbbreviationPWS
    Full namePrader-Willi syndrome
    Policy contextVykat XR initial approval requires PWS confirmation by genetic testing indicating a mutation on chromosome 15
  5. Baseline Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score is at least 13.HQ-CT ≥ 13
  6. The dose does not exceed 5.8 mg/kg per day.≤ 5.8 mg/kg/day
  7. The dose does not exceed 525 mg per day.≤ 525 mg/day
  8. Dose increase, when applicable: If the request is for a dose increase, the new dose does not exceed 5.8 mg/kg per day.≤ 5.8 mg/kg/day
  9. Dose increase, when applicable: If the request is for a dose increase, the new dose does not exceed 525 mg per day.≤ 525 mg/day